Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11M
- Development stage
- Unknown
- Lead developer
- Alvit LCS Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
11M is an innovative line of IP-protected, fixed-dose combination products developed under a joint venture between Alvit LCS Pharma and Mycolivia. The product line combines the synergistic therapeutic elements of medicinal mushrooms and cannabinoids to target the symptoms of various medical indications. By integrating the bioactive compounds of medicinal mushrooms with cannabinoids, 11M aims to enhance the overall therapeutic efficacy of cannabis-based treatments.
- Brand names
- 11M
Beyond the preview
Go deeper on 11M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11M.